Publication | Closed Access

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease

Functional SelectivityMedicineNeuropharmacologyPharmacotherapyNeuroscienceNeurologyNeuroprotectionL-dopa-induced DyskinesiaDopaminePharmacologyMild PotentiationMptp-lesioned Marmoset Model